Clinical Trial

Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings

Recruiting
View on ClinicalTrials.gov →
Summary
Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA through an increase in uptake rates of cervical cancer screening as compared to offering clinician-sampling HPV DNA testing alone. The hypothesis is that offering additional self-sampling will increase the detection of high-risk HPV DNA by at least 7.7%.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-25; most recent amendment 2025-02-05.
Status change: Not Yet Recruiting → Recruiting 2024-11-12
Trial Details
NCT Number NCT06528184
Lead Sponsor National Healthcare Group Polyclinics
Collaborators: National Healthcare Group, Singapore, KK Women's and Children's Hospital
Conditions Uterine Cervical Neoplasms
Enrollment 650 participants
Start Date 2024-08-05
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-10